tirzepatide risk not linked to increased for depression Tirzepatide and Cancer Risk in
Description
The SURMOUNT trials documented several common adverse effects

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Lets take a closer look at both to help you make an informed decision
Will continue this to meet my goals

Its standard for Phase 3 trials to be sponsor-funded, but its useful context when the first figures come through a press release rather than a journal

There isnt enough human data to say for certain, but animal studies raise some concerns
